Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.038
Filter
1.
Int J Infect Dis ; 2022.
Article in English | PubMed | ID: covidwho-2028099

ABSTRACT

Severe neurological disorders and vascular events during COronaVIrus Disease-2019 (COVID-19) have been described. Here, we describe the first case of a female patient infected with Omicron SARS-CoV-2 BA.2 Variant of Concern (VoC) meningitis with newly diagnosed central demyelinating disease.

2.
SSRN; 2022.
Preprint in English | SSRN | ID: ppcovidwho-343361

ABSTRACT

Background: Immune imprinting plays a crucial role in subsequent antibody responses against SARS-CoV-2. However, unknown prior exposures due to subclinical infections may confound the results. With a low prevalence of COVID-19 before 2022 (<0.2% of the population), the chance of unknown prior SARS-CoV-2 exposure is low in Hong Kong, which provides a unique opportunity to accurately delineate the importance immune imprinting. Methods: We determined and compared the neutralizing antibody titer against SARS-CoV-2 ancestral strain and Omicron sublineages for patients with different infection or vaccination exposure history between 2020 and 2022. Findings: Individuals infected with SARS-CoV-2 ancestral strain in 2020 and boosted with only a single dose of BNT162b2 (2020-infected/1x-BNT162b2) had high serum neutralizing antibody titers against Omicron variant BA.2, BA.2.12.1 and BA.4/5 sublineages. The levels of neutralizing antibody against ancestral or Omicron strains in the 2020-infected/1x-BNT162b2 group were at least 8.6-fold higher than COVID-19-naïve individuals with 2 doses of BNT162b2, and were comparable to the levels seen among groups with 3 exposures to SARS-CoV-2 spike protein by vaccination or infection, including those with Omicron infection. Among patients with Omicron BA.2 infection, those with prior BNT162b2 vaccine had higher neutralization antibody titers against ancestral strain, BA.2 and BA.5 than those with prior CoronaVac. Interpretation: Our data suggest that imprinting with ancestral strain infection confer robust and broad humoral immune response after subsequent exposures. Patient imprinted with inactivated whole virion COVID-19 vaccines will likely require additional vaccine doses even after Omicron variant infection in order to prevent reinfection with Omicron BA.5 or other upcoming variants.

3.
SSRN; 2022.
Preprint in English | SSRN | ID: ppcovidwho-343355

ABSTRACT

Background: Omicron variants appear in many areas around the world. Omicron infection rate is currently very high in the world. It let to many countries to lockdown. The variant risk assessment and new ones have been a high level of uncertainty. Methods: We applied time series regression models. The model training to across all data. By this point in the modeling profess, the optimal hyperparameters that gave the best performance on the outer loop validation datasets have already been identified. Incorporating the optimal hyperparameters in a final model would occur in a new defined modeling wrapper function. Specific validation datasets that are given for our measurements are taken daily and set some arguments to skip between validation datasets. Also, custom validation windows were defined with vectors of start and stop dates. Results: 58 days for UK research data at 9 areas in November and December 2021 show that, Northwest England was the most infection cases: values at November 2021 were 11305 for total, 9811 for n(confirmed cases), 86.8% of infection rate, confidence low was 86.14% and 87.40% for confidence high;values for November 22, 2021 were 16985 for total, 15415 for confirmed cases, 90.8% of infection rate, 90.3% and 91.8 for confidence high, and values at November 26, 2021 were 11553 for the total, 10909 fof confirmed cases, 94.4% of infection rate, confidence low was 93.99 and 94.83 for confidence high, accordingly. Also, the confirmed and suspected cases would be higher peak. Conclusions: Omicron infection impact highlights that the variants have elusiveness, transmissibility, and changeability. Thus, it leads to global public health problems. We observed the cases in population density regions and the most deprived locations were easily higher infection and public emergency. Therefore, the preventive and protective measurement in these areas is very important.

4.
SSRN; 2022.
Preprint in English | SSRN | ID: ppcovidwho-343318

ABSTRACT

Since the beginning of March 2022, the epidemic due to the Omicron variant has developed rapidly in Jilin Province. To figure out the key controlling factors and validate the model to show the success of the Zero-COVID policy in the province, we constructed a Recursive Zero-COVID Model quantifying the strength of the control measures, and defined the control reproduction number as an index for describing the intensity of interventions. Parameter estimation and sensitivity analysis were employed to estimate and validate the impact of changes in the strength of different measures on the intensity of public health preventions qualitatively and quantitatively. The recursive Zero-COVID model predicted that the elimination of cases at the community level of the Changchun and Jilin Cities to be on April 8 and April 17, respectively, which are consistent with the real situation. Our results showed that the strict implementation of control measures and adherence of the public are crucial for controlling the epidemic. It is also essential to strengthen the control intensity even at the final stage to avoid the rebound of the epidemic. In addition, the control reproduction number we defined in the paper is a novel index to measure the intensity of the prevention and control measures of public health.

5.
SSRN; 2022.
Preprint in English | SSRN | ID: ppcovidwho-343223

ABSTRACT

The association of S-protein of SARS-CoV-2 beta-coronavirus to ACE2 receptors of the human epithelial cells determines its contagiousness and pathogenicity. We compute pH-dependent electric potential on the surface of the interacting globular proteins (ACE2 receptor, S-protein, its S1-subunit, and their complex) and alteration of Gibbs free energy at association of the wild-type strain and omicron variant. The isoelectric points: pI 5.4 (ACE2 receptor), pI 7.3 (S-protein, wild type), pI 8.8 (S1-subunit, wild type), pI 9.5 (S1-subunit, omicron variant) disclose that at pH 5.5–7.4 (physiological conditions) the S1-ACE2 association is determined by electrostatic attraction of the oppositely charged receptor and viral protein. The comparison of the local electrostatic potentials of the omicron variant and wild-type shows that the point mutations alter the electrostatic potential in a relatively small area on the surface of receptor-binding domain (RBD) of S1-subunit. The appearance of 7 charge-changing point mutations in RBD (equivalent to 3 additional positive charges) leads to pI-shifts with 0.5 pH-unit and to stronger S1-ACE2 association at pH 5.5 (the respiratory tract) and weaker one at pH 7.4 (the blood plasma);that reveals the cause for the higher contagiousness but lower pathogenicity of the omicron variant relative to the wild-type strain.

7.
Annals of Phytomedicine-an International Journal ; 10:S77-S85, 2021.
Article in English | Web of Science | ID: covidwho-2026890

ABSTRACT

Viral mutations can become more common as a result of natural selection, random genetic drift or recent epidemiological trends. Even more difficult is to determine whether a single mutation will affect the fate of an illness or a pandemic. World Health Organization designated the latest strain of SARS-CoV-2, the Omicron, as a "variant of concern" as more countries are reporting cases, and it contains a unique mix of mutations that might help it spread faster. Mutations in the SARS-CoV-2 strains at the high rates lead to the in effectiveness of vaccines and developed drugs. As the mutations occur only on the spike proteins of the viral particles, targeting other vital enzymes, i.e., proteases for drug discovery paves way for potential drug candidate irrespective of the mutations. So, the present study focuses on identifying the phytocompounds from Datura metal L. inhibiting the SARS-CoV-2 proteases. The druglikeness, PASS predictions and ADMET properties of the selected compounds were performed. 31 compounds were identified from the KNApSAck database and subjected to molecular docking studies. From the analysis, 7 compounds. Withametelin I, Withametelin J, Withametelin K, Withametelin L, Withametelin M, Withametelin N and Withametelin O showed significant binding energies and ADMET values. Therefore, these compounds can be further utilized for development of novel drugs for treatment of SARS-CoV-2 infections.

8.
Rev Invest Clin ; 74(4):175-180, 2022.
Article in English | PubMed | ID: covidwho-2026321

ABSTRACT

BACKGROUND: Relatively low SARS-CoV-2 reinfection rates have been reported in vaccinated individuals, but updates considering the Omicron variant are lacking. OBJECTIVES: The objective of the study was to provide a current estimate of the SARS-CoV-2 reinfection rate in a highly immunized population. METHODS: A prospective cohort of Mexican hospital workers was followed (March 2020-February 2022). Reinfection was defined as the occurrence of two or more episodes of COVID-19 separated by a period of ≥ 90 days without symptoms. The reinfection rate was calculated as the number of reinfection episodes per 100,000 persons per day. RESULTS: A total of 3732 medical consultations were provided to 2700 workers, of whom 1388 (51.4%) were confirmed COVID-19 cases. A total of 73 reinfection cases were identified, of whom 71 (97.3%) had completed their primary vaccination series and 22 (30.1%) had had a booster dose before the second episode. The overall reinfection rate was 23.1 per 100,000 persons per day (as compared to a rate of 1.9 per 100,000 persons per day before the Omicron wave). CONCLUSIONS: The SARS-CoV-2 reinfection rate rose significantly during the Omicron wave despite a high primary vaccination coverage rate. Almost one-third of reinfected workers had a vaccine booster ≥ 14 days before the last COVID-19 episode.

9.
EMBO Mol Med ; : e16109, 2022.
Article in English | PubMed | ID: covidwho-2025767

ABSTRACT

Monoclonal antibodies targeting the SARS-CoV-2 spike (S) neutralize infection and are efficacious for the treatment of COVID-19. However, SARS-CoV-2 variants, notably sublineages of B.1.1.529/omicron, have emerged that escape antibodies in clinical use. As an alternative, soluble decoy receptors based on the host entry receptor ACE2 broadly bind and block S from SARS-CoV-2 variants and related betacoronaviruses. The high-affinity and catalytically active decoy sACE2(2) .v2.4-IgG1 was previously shown to be effective against SARS-CoV-2 variants when administered intravenously. Here, inhalation of aerosolized sACE2(2) .v2.4-IgG1 increased survival and ameliorated lung injury in K18-hACE2 mice inoculated with P.1/gamma virus. Loss of catalytic activity reduced the decoy's therapeutic efficacy, which was further confirmed by intravenous administration, supporting dual mechanisms of action: direct blocking of S and turnover of ACE2 substrates associated with lung injury and inflammation. Furthermore, sACE2(2) .v2.4-IgG1 tightly binds and neutralizes BA.1, BA.2, and BA.4/BA.5 omicron and protects K18-hACE2 mice inoculated with a high dose of BA.1 omicron virus. Overall, the therapeutic potential of sACE2(2) .v2.4-IgG1 is demonstrated by inhalation route and broad neutralization potency persists against highly divergent SARS-CoV-2 variants.

10.
Journal of Medical Cases ; 13(8):380-385, 2022.
Article in English | Scopus | ID: covidwho-2025721

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic emerged as a world crisis in 2019 and started a global search for optimal therapeutic regimen including vaccines, antiviral agents, and recently monoclonal antibody therapy. Clinical trials are currently underway for the efficacy of several neutralizing monoclonal antibodies against COVID-19. The evolution of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with immune evasion capacity has created a challenge for the healthcare workers with urgent need for prospective studies to determine functionality of monoclonal antibody therapy and their role in the reduction of hospitalization for disease severity. Herein, we report three cases of COVID-19 during the beginning of the spread of Omicron variants that were hospitalized after treatment with monoclonal antibody therapy in the emergency department. All the patients showed progression of the disease on imaging and were treated with dexamethasone, remdesivir and anticoagulation based on the symptoms and contraindications. Two of the patients recovered and were discharged with out-patient follow-up;however, one patient expired in the hospital. Monoclonal antibody therapy is a promising treatment to limit the progression of COVID-19 and reduce the hospital strain specifically in small community hospitals. Limited information is available about their efficacy in the new viral variants. These cases emphasize the need of future prospective study and randomized controlled trials to illustrate the utilization of monoclonal antibodies as a therapeutic modality in patients infected with the variants of SARS-CoV-2. © The authors ;Journal compilation J Med Cases and Elmer Press Inc™ ;www.journalmc.org This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

11.
Eur J Case Rep Intern Med ; 9(8):003502, 2022.
Article in English | PubMed | ID: covidwho-2025604

ABSTRACT

We describe four cases of COVID-19 infection during the Omicron wave, in patients treated with anti-CD20 monoclonal antibodies. All cases follow a similar biphasic clinical course consisting of respiratory deterioration, which occurred a few weeks after convalescence from initial mild to asymptomatic infection. Possible explanations are discussed. LEARNING POINTS: Four cases of COVID-19 infection in anti-CD20 treated patients are described.These cases display a unique biphasic course that was previously undescribed: respiratory deterioration weeks after convalescence.Awareness of such a course and rapid utilisation of bronchoalveolar lavage will lead to quicker diagnosis and more timely, appropriate treatment.

12.
Biosci Trends ; 2022.
Article in English | PubMed | ID: covidwho-2025185

ABSTRACT

During a six-week period from July 20 to August 31, 2022, Japan experienced its highest level of COVID-19 infection ever, with an average of nearly 200,000 new infections per day nationwide. Cases requiring inpatient care peaked at 1,993,062. Twenty-seven prefectures (out of 47 prefectures) had an average hospital bed occupancy of 50% or higher, and bed occupancy in Kanagawa in particular reached 98% in mid-August. In Tokyo, bed occupancy by patients with severe COVID-19 reached 57% and peaked at 64% in mid-August. Although the number of new infections per day has decreased since September, hospital bed occupancy, the number of severe cases, and deaths remain high nationwide. Efforts including vaccination campaigns, domestic surveillance, and routine infection control measures based on the varied knowledge that the Japanese public already has should be thoroughly implemented to reduce the number of the infected in order to avoid an increase the number of serious cases and deaths.

13.
Journal of Young Pharmacists ; 14(3):283-288, 2022.
Article in English | Web of Science | ID: covidwho-2025170

ABSTRACT

Background: The Severe Acute Respiratory Coronavirus (SARS-CoV-2) has emerged in a variety of forms since its first appearance in early December 2019. The Omicron variation (B.1.1.529) was recently confirmed as a relatively new Variant of Concern (VOC). There are several mutations in this S-protein, making it an exclusively lethal version of the protein. Omicron variants feature multiple mutations clustered in a region of S protein that is the principal target of antibodies, and these mutations may have an impact on the binding affinities of antibodies to the S protein, as demonstrated by structural analysis. Materials and Methods: Google, Sciencedirect, Web of science, and ResearchGate databases have been explored for potentially existing research to obtain the most emerging trends and up-to-date metadata on various perspectives of Omicron variants. Conclusion: There is evidence that the Omicron variant's mutations may interfere with antibody binding in people who have been exposed to the SARS-CoV-2 virus in the past. At the moment, there is very little information on the Omicron version. Therefore, mutation dispersion evaluations, evolutionary links to previous variants, and putative structural effects on antibody binding effects are all explored in this work. Results: In the current state of pandemic crises, the comprehension of Omicron will pave a path for healthcare professionals to treat infectious conditions very well.

14.
Frontiers in Public Health ; 10, 2022.
Article in English | Web of Science | ID: covidwho-2022934

ABSTRACT

Based on the epidemic data of COVID-19 in 50 states of the United States (the US) from December 2021 to January 2022, the spatial and temporal clustering characteristics of COVID-19 in the US are explored and analyzed. First, the retrospective spatiotemporal analysis is performed by using SaTScan 9.5, and 17 incidence areas are obtained. Second, the reliability of the results is tested by the circular distribution method in the time latitude and the clustering method in the spatial latitude, and it is confirmed that the retrospective spatiotemporal analysis accurately measures in time and reasonably divides regions according to the characteristics in space. Empirical results show that the first-level clustering area of the epidemic has six states with an average relative risk of 1.28 and the second-level clustering area includes 18 states with an average relative risk of 0.86. At present, the epidemic situation in the US continues to expand. It is necessary to do constructive work in epidemic prevention, reduce the impact of epidemic, and effectively control the spread of the epidemic.

15.
Frontiers in Medicine ; 9, 2022.
Article in English | Web of Science | ID: covidwho-2022776

ABSTRACT

Seroconversion rates after COVID-19 vaccination are significantly lower in kidney transplant recipients compared to healthy cohorts. Adaptive immunization strategies are needed to protect these patients from COVID-19. In this prospective observational cohort study, we enrolled 76 kidney transplant recipients with no seroresponse after at least three COVID-19 vaccinations to receive an additional mRNA-1273 vaccination (full dose, 100 mu g). Mycophenolic acid was withdrawn in 43 selected patients 5-7 days prior to vaccination and remained paused for 4 additional weeks after vaccination. SARS-CoV-2-specific antibodies and neutralization of the delta and omicron variants were determined using a live-virus assay 4 weeks after vaccination. In patients with temporary mycophenolic acid withdrawal, donor-specific anti-HLA antibodies and donor-derived cell-free DNA were monitored before withdrawal and at follow-up. SARS-CoV-2 specific antibodies significantly increased in kidney transplant recipients after additional COVID-19 vaccination. The effect was most pronounced in individuals in whom mycophenolic acid was withdrawn during vaccination. Higher SARS-CoV-2 specific antibody titers were associated with better neutralization of SARS-CoV-2 delta and omicron variants. In patients with short-term withdrawal of mycophenolic acid, graft function and donor-derived cell-free DNA remained stable. No acute rejection episode occurred during short-term follow-up. However, resurgence of prior anti-HLA donor-specific antibodies was detected in 7 patients.

16.
Front Immunol ; 13:940562, 2022.
Article in English | PubMed | ID: covidwho-2022718

ABSTRACT

BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is currently the dominant variant globally. This third interim analysis of a living systematic review summarizes evidence on the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine (vaccine effectiveness, VE) and duration of protection against Omicron. METHODS: We systematically searched literature on COVID-19 for controlled studies, evaluating the effectiveness of COVID-19 vaccines approved in the European Union up to 14/01/2022, complemented by hand searches of websites and metasearch engines up to 11/02/2022. We considered the following comparisons: full primary immunization vs. no vaccination, booster immunization vs. no vaccination, and booster vs. full primary immunization. VE against any confirmed SARS-CoV-2 infection, symptomatic, and severe COVID-19 (i.e., COVID-19-related hospitalization, ICU admission, or death) was indicated, providing estimate ranges. Meta-analysis was not performed due to high study heterogeneity. The risk of bias was assessed with ROBINS-I, and the certainty of the evidence was evaluated using GRADE. RESULTS: We identified 26 studies, including 430 to 2.2 million participants, which evaluated VE estimates against infections with the SARS-CoV-2 Omicron variant. VE against any confirmed SARS-CoV-2 infection ranged between 0-62% after full primary immunization and between 34-66% after a booster dose compared to no vaccination. VE range for booster vs. full primary immunization was 34-54.6%. After full primary immunization VE against symptomatic COVID-19 ranged between 6-76%. After booster immunization VE ranged between 3-84% compared to no vaccination and between 56-69% compared to full primary immunization. VE against severe COVID-19 ranged between 3-84% after full primary immunization and between 12-100% after booster immunization compared to no vaccination, and 100% (95% CI 71.4-100) compared to full primary immunization (data from only one study). VE was characterized by a moderate to strong decline within 3-6 months for SARS-CoV-2 infections and symptomatic COVID-19. Against severe COVID-19, protection remained robust for at least up to 6 months. Waning immunity was more profound after primary than booster immunization. The risk of bias was moderate to critical across studies and outcomes. GRADE certainty was very low for all outcomes. CONCLUSIONS: Under the Omicron variant, the effectiveness of EU-licensed COVID-19 vaccines in preventing any SARS-CoV-2 infection is low and only short-lasting after full primary immunization, but can be improved by booster vaccination. VE against severe COVID-19 remains high and is long-lasting, especially after receiving the booster vaccination.

17.
Journal of Korean Medical Science ; 37(34), 2022.
Article in English | Web of Science | ID: covidwho-2022638

ABSTRACT

Background: Due to the higher transmissibility and increased immune escape of the omicron variant of severe acute respiratory syndrome coronavirus 2, the number of patients with coronavirus disease 2019 (COVID-19) has skyrocketed in the Republic of Korea. Here, we analyzed the change in trend of the number of confirmed COVID-19 cases in the Korean military after the emergence of the omicron variant on December 5, 2021. Methods: An interrupted time-series analysis was performed of the daily number of newly confirmed COVID-19 cases in the Korean military from September 1, 2021 to April 10, 2022, before and after the emergence of the omicron variant. Moreover, the daily number of newly confirmed COVID-19 cases in the Korean military and in the population of Korean civilians adjusted to the same with military were compared. Results: The trends of COVID-19 occurrence in the military after emergence of the omicron variant was significantly increased (regression coefficient, 23.071;95% confidence interval, 16.122-30.020;P < 0.001). The COVID-19 incidence rate in the Korean military was lower than that in the civilians, but after the emergence of the omicron variant, the increased incidence rate in the military followed that of the civilian population. Conclusion: The outbreak of the omicron variant occurred in the Korean military despite maintaining high vaccination coverage and intensive non-pharmacological interventions.

18.
Horm Mol Biol Clin Investig ; 2022.
Article in English | Web of Science | ID: covidwho-2022040

ABSTRACT

COVID-19 emerged in Wuhan, China, but was caused by the original coronavirus, severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV2). In early 2020, there was a widespread breakout of cases well over world, resulting in an epidemic that rapidly escalated to become a pandemic. This abruptly shook the global healthcare system. The emergence of the alpha, beta, and delta SARS-CoV-2 were associated with new waves of infections, sometimes across the entire world but until this month i.e., between Nov-Dec, 2021, Delta variant reigned supreme until the emergence of a newer variant i.e., Omicron (B.1.1.529) of SARS-CoV-2. Delta had 13 mutations. Of these, nine are in the spike protein, the protrusion on the surface of the virus that helps it latch onto human cells. Specifically, two are in a molecular hook, called the "receptor-binding domain". Omicron, a creation caused by monstrous mutations. At least 32 mutations are in the spike protein and 10 in the receptor-binding domain. was designated a COVID-19 variant of concern (VoC) by the World Health Organization (WHO) on 26th November 2021. Structurally, the omicron variant has shown too mutated at antibody binding sites which would leverage them for escaping the possible immune response by the body. We don't yet know much about the other alterations and how they might affect the virus's behavior. Omicron COVID-19 strain after identifying individuals with symptoms that were not the same as those seen in the Delta form. People with night sweats have also been reported. The new omicron variant has more mutations than the prevailing rampant delta virus. This makes the newer variant more transmissible, better able to evade itself from various vaccines readily available in the current scenario. These overall increases in the percentage changes in a single day cases of COVID-19 reported cases can be attributed to the beginning of third wave or can be speculated as newer surge of omicron variant cases. Yet another new variant has been detected in France with 46 mutations and 37 deletions in its genetic code, many affecting the spike protein. 'B.1.640.2' is the current nomenclature for this variation.

19.
Journal of Asian & African Studies (Sage Publications, Ltd.) ; : 1, 2022.
Article in English | Academic Search Complete | ID: covidwho-2020717

ABSTRACT

The tourism industry sustains the economies of many nations across the globe through contributing to the Gross Domestic Products (GDP);creation of employment and infrastructure development. However, its sustainability is vulnerable to various temporal and spatial environmental, socio-economic and political events. In the Zimbabwe case, the politico-economic crises of the 2000s and the COVID-19 pandemic have variedly impacted on the prevalence of tourism with the actors (such as employees, tourists and recreational facility owners) involved in this industry having been seriously impacted. Using the precarity conceptual framework, this article critically analyses the impact of the politico-economic crises induced by the Fast Track Land Reform Programme of the early 2000s and the COVID-19 pandemic on the actors involved in tourism. Information regarding the impact of the political crises and COVID-19 pandemic on tourism in Kariba town is missing in the literature, yet Kariba is one of the most popular tourist destinations in Zimbabwe and Southern Africa. The article discusses the precarity of these tourism actors in the context of the politico-economic crises as well as the COVID-19 pandemic. We define ‘precarity’ as a condition of vulnerability and uncertainty. Our results indicate that for employees, these factors have resulted in uncertainty in the tourism business with some shutting down and others scaling down their operations resulting in redundancy and vulnerability of the workers. For tourists, the successive lockdowns and surge in COVID-19 cases in Zimbabwe resulted in (re)booking and (re)cancellation of bookings;the politico-economic crises resulted in fear among the potential clients and a drop in the number of international tourists. The recreational and accommodation service operators have had the challenge of making food (and other resources) orders for trips that are eventually cancelled due to the surge in the COVID-19 cases. The article draws from data gathered in 2021 through face-to-face interviews with different stakeholders in the tourism industry including employees, hotel and boat owners, Zimbabwe Tourism Authority officials and local politicians in Kariba resort town. [ FROM AUTHOR] Copyright of Journal of Asian & African Studies (Sage Publications, Ltd.) is the property of Sage Publications, Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

20.
2nd International Conference on Computing Advancements: Age of Computing and Augmented Life, ICCA 2022 ; : 156-164, 2022.
Article in English | Scopus | ID: covidwho-2020419

ABSTRACT

In the advent of a global pandemic, the necessity for early COVID-19 suspect detection and quarantine is of paramount importance. Medical research indicates that a high fever provides a general litmus of whether or not a person is infected with Coronavirus. Among several available solutions, thermal imaging has proven to be a better contactless screening procedure. It enables fast and easy detection of fever from a reasonable distance. In this research, a solution named Thermique is proposed. It is a cheap, easy to mass-produce, and automated AI-enabled thermal screening platform that combines facial detection, instant contactless temperature scanning, and RFID logging, while also providing an integrated defense against the spread of COVID-19 in a particular facility. Consisting of only off-the-shelf electronic components, this solution can be implemented with a significantly minimized cost, compared to its similar-function providing alternatives available on the market. To design and implement Thermique, a system architecture was developed for the platform, the details of which are highlighted within this paper. After the development of the prototype, several analytical evaluations of the system have been conducted, including the system's performance, and overall usability. © 2022 ACM.

SELECTION OF CITATIONS
SEARCH DETAIL